Navigation Links
LUNGevity Foundation Praises Recent FDA Approval of New Lung Cancer Treatment Drug XALKORI® (crizotinib)
Date:8/27/2011

WASHINGTON, Aug. 27, 2011 /PRNewswire-USNewswire/ -- LUNGevity Foundation applauds the US Food and Drug Administration's (FDA) recent approval of XALKORI® (crizotinib) to treat lung cancer. The drug, introduced by Pfizer, Inc. showed such promise in early trials that it was given "fast track" status by the FDA.

LUNGevity Foundation President Andrea Stern Ferris called the FDA's approval of XALKORI incredibly positive, saying: "The trial results are remarkable, strengthening the body of evidence that targeted therapies hold great promise in treating this deadly cancer. Lung cancer is the nation's number one cancer killer. The federal government and the private sector need to invest in accelerating all of the other promising research now underway that can change the way we diagnose and treat lung cancer and save lives."

XALKORI is a member of a new class of drugs that work by inhibiting the anaplastic lymphoma kinase (ALK) gene. Alterations of this gene are thought to drive tumor development in certain cancers. XALKORI is approved for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test.  About 10,000 of the 222,000 Americans diagnosed with non-small-cell lung cancer each year could be expected to have the genetic abnormality. William Pao, associate professor of medicine, Vanderbilt-Ingram Cancer Center, said: "The approval of crizotinib is an exciting development.  It further validates the idea that lung cancers are very different at the molecular level, even though they may look similar under the microscope, and should be treated accordingly.  It also shows how fast translational research is becoming medical practice. ALK fusions in lung cancer were only first reported in 2007, and by 2010, we already had reports on the activity of a specific ALK inhibitor in patients with ALK fusion-positive lung cancer.  Hopefully, this is just the beginning of many new benefits for lung cancer patients."

In December 2010, the FDA granted Pfizer's XALKORI NDA Fast Track status, a designation that speeds the review of drugs for serious or life-threatening diseases and for an unmet medical need. Drugs that may offer major advances in treatment or may provide a treatment where no adequate therapy exists usually are given the status. The FDA then granted XALKORI Priority Review status, which shortened the review time from 10 months to six months.

Dr. Charles Rudin, director, Lung Cancer Therapeutics Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and a member of LUNGevity Foundation's scientific advisory board said: "Crizotinib is a prime example of successful deployment of a targeted inhibitor against a driver mutation in lung cancer.  Like the EGFR inhibitors in EGFR-mutant lung cancer, crizotinib is remarkably effective against ALK-translocated lung cancer." He also pointed out the urgency of additional research, saying, "As with the EGFR inhibitors, acquired resistance to this targeted inhibitor is already emerging as an important problem, and is a focus of ongoing research in the field."

About LUNGevity Foundation

The mission of LUNGevity Foundation is to have a meaningful and immediate impact on improving lung cancer survival rates, ensure a higher quality of life for lung cancer patients, and provide a community for those impacted by lung cancer.

In order to accomplish its mission, LUNGevity funds the most promising research into the early detection and successful treatment of lung cancer. LUNGevity also supports the largest national grassroots lung cancer network.

LUNGevity seeks to inspire the nation to commit to ending lung cancer.

For more information, please visit www.lungevity.org.

About Lung Cancer

  • Lung cancer impacts 1 in 14 Americans and is the number one cancer killer.
  • About 60 percent of Americans diagnosed with lung cancer either never smoked a cigarette in their lives or had quit smoking.
  • Less than 16 percent of people diagnosed with lung cancer survive 5 years post-diagnosis because of limited early detection opportunities.
  • There is no widely available, effective early diagnostic test available today.


'/>"/>
SOURCE LUNGevity Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alzheimers Drug Discovery Foundation Supports Madera Biosciences with a Grant to Advance Novel Drug Candidates for Alzheimers Disease
2. Enox Biopharma, Inc. Will Be Granted its Foundation Patent
3. Foundation Venture Capital Group Investment Shows Promise in Diagnosis of Alzheimers Disease Using a Drop of Blood
4. The Pulmonary Hypertension Association and MedicAlert Foundation Form Alliance to Safeguard Patients
5. Futbol Club Barcelona and the Bill & Melinda Gates Foundation Team Up to End Polio and Give Every Child an Equal Shot at Life
6. Merz Pharmaceuticals Commends The Benign Essential Blepharospasm Research Foundation On 30 Years Of Community Support
7. Lilly Donation to Patient Advocate Foundation Expands Services and Access for Patients With Most Common Form of Lung Cancer
8. Henry Schein Cares Foundation and Henry Schein Cares Contribute More Than $375,000 in Financial and Product Donations for Disaster Relief Efforts on Three Continents
9. Patient Advocate Foundation Announces Significant Operational, Technology Enhancements to Co-Pay Relief (CPR) Program
10. Amerigroup Foundation Presents Grant to Rx Partnership
11. ECRI Institute and Health Care Improvement Foundation Launch CT Radiation Safety Collaborative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 According to a ... (Standard Pen Needles, Safety Pen Needles), Needle Length (4mm, ... Hormone), Mode of Purchase (Retail, Non-Retail) - Trends & ... studies the market for the forecast period of 2016 ... 2.81 Billion by 2021 from USD 1.65 Billion in ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 27, 2016 , ... "FCPX editors can now reveal their media with growing ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings ... users can now reveal the media of their split screens with growing colorful panels. ...
(Date:6/27/2016)... , ... June 27, 2016 , ... TopConsumerReviews.com recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
Breaking Medicine News(10 mins):